175 related articles for article (PubMed ID: 18279516)
21. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.
Parada B; Sereno J; Reis F; Teixeira-Lemos E; Garrido P; Pinto AF; Cunha MF; Pinto R; Mota A; Figueiredo A; Teixeira F
Cancer Biol Ther; 2009 Sep; 8(17):1615-22. PubMed ID: 19571668
[TBL] [Abstract][Full Text] [Related]
22. Effects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.
Miliaras S; Anogeianaki A; Meditskou S; Kefala V; Koutsonikolas D; Liangouris J; Anogianakis G; Miliaras D
Int J Immunopathol Pharmacol; 2009; 22(2):323-32. PubMed ID: 19505386
[TBL] [Abstract][Full Text] [Related]
23. [Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].
Kang HF; Wang XJ; Liu XX; Dai ZJ; Xue FJ; Xue XH
Ai Zheng; 2006 Nov; 25(11):1346-50. PubMed ID: 17094899
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
[TBL] [Abstract][Full Text] [Related]
25. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Mustafa A; Kruger WD
Clin Cancer Res; 2008 Aug; 14(15):4935-42. PubMed ID: 18676768
[TBL] [Abstract][Full Text] [Related]
26. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
[TBL] [Abstract][Full Text] [Related]
27. Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.
Jang TJ; Jung HG; Jung KH; O MK
Int J Exp Pathol; 2002 Aug; 83(4):173-82. PubMed ID: 12485462
[TBL] [Abstract][Full Text] [Related]
28. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Subbaramaiah K; Howe LR; Port ER; Brogi E; Fishman J; Liu CH; Hla T; Hudis C; Dannenberg AJ
Cancer Res; 2006 May; 66(10):5504-11. PubMed ID: 16707480
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids.
Lu S; Zhang X; Badawi AF; El-Sohemy A; Archer MC
Cancer Lett; 2002 Oct; 184(1):7-12. PubMed ID: 12104042
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
32. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.
Levitt RJ; Buckley J; Blouin MJ; Schaub B; Triche TJ; Pollak M
Biochem Biophys Res Commun; 2004 Apr; 316(2):421-8. PubMed ID: 15020235
[TBL] [Abstract][Full Text] [Related]
33. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
[TBL] [Abstract][Full Text] [Related]
34. The effect of celecoxib on the development of diethylnitrosamine-induced liver tumors in rats.
Galant LW; de Mattos AA; Menti E; Valiatti FB; de Mattos AZ; Porawski M; Hartmann A; Rhoden CR
Ann Hepatol; 2013; 12(3):425-33. PubMed ID: 23619259
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Saito T; Tamura D; Asano R
Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
[TBL] [Abstract][Full Text] [Related]
36. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.
Schroeder CP; Kadara H; Lotan D; Woo JK; Lee HY; Hong WK; Lotan R
Cancer Res; 2006 Oct; 66(19):9762-70. PubMed ID: 17018636
[TBL] [Abstract][Full Text] [Related]
37. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.
Yu J; Tang BD; Leung WK; To KF; Bai AH; Zeng ZR; Ma PK; Go MY; Hu PJ; Sung JJ
World J Gastroenterol; 2005 Jan; 11(1):41-5. PubMed ID: 15609394
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
[TBL] [Abstract][Full Text] [Related]
39. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Chow LW; Yip AY; Chu WP; Loo WT; Toi M
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):112-9. PubMed ID: 21236344
[TBL] [Abstract][Full Text] [Related]
40. The effect of flutamide and tamoxifen on sex hormone-induced mammary carcinogenesis and pituitary adenoma.
Leung G; Tsao SW; Wong YC
Breast Cancer Res Treat; 2002 Mar; 72(2):153-62. PubMed ID: 12038706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
